• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Metsera Inc.

    6/3/25 4:30:15 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Metsera, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    59267L107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Validae Health, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,767,462.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Population Health Partners GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,767,462.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Limited Liability Company


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Christopher Whitten Bernard
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    369,182.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    369,182.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    13,136,644.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.5 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Christopher T. Cox
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    18,914.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    18,914.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,786,376.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Clive A. Meanwell
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    67,438.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    67,438.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,834,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Metsera, Inc.
    (b)Address of issuer's principal executive offices:

    3 World Trade Center, 175 Greenwich Street, New York, NY, 10007
    Item 2. 
    (a)Name of person filing:

    Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: Validae Health, L.P. Population Health Partners GP, LLC Christopher Whitten Bernard Christopher T. Cox Clive A. Meanwell
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is c/o Population Health Partners, L.P., 1200 Morris Turnpike, Suite 3005, Short Hills, NJ 07078.
    (c)Citizenship:

    Validae Health, L.P. and Population Health Partners GP, LLC are organized under the laws of the State of Delaware. Clive A. Meanwell is a citizen of the United Kingdom. The remaining Reporting Persons are citizens of the United States.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    59267L107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4. The ownership information presented herein represents beneficial ownership of Common Stock as of the date of this filing, based upon 105,055,538 shares of Common Stock outstanding as of May 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 12, 2025. Validae Health, L.P. is the record holder 12,767,462 shares of Common Stock. Population Health Partners GP, LLC ("PHP GP LLC"), is the sole general partner of Validae Health, L.P., and may be deemed to beneficially own the shares of Common Stock held by Validae Health, L.P. Christopher Whitten Bernard, Christopher T. Cox and Clive A. Meanwell are members of PHP GP LLC and may be deemed to share the power to direct the disposition and vote of the shares held by Validae Health, L.P. Additionally, Christopher Whitten Bernard is the beneficial owner of 369,182 shares of Common Stock underlying stock options that are vested or will vest within 60 days of the date hereof, Christopher T. Cox is the beneficial owner of 18,914 shares of Common Stock underlying stock options that are vested or will vest within 60 days of the date hereof and Clive A. Meanwell is the beneficial owner of 67,438 shares of Common Stock underlying stock options that are vested or will vest within 60 days of the date hereof.
    (b)Percent of class:

    See cover pages
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See cover pages

     (ii) Shared power to vote or to direct the vote:

    See cover pages

     (iii) Sole power to dispose or to direct the disposition of:

    See cover pages

     (iv) Shared power to dispose or to direct the disposition of:

    See cover pages

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Validae Health, L.P.
     
    Signature:/s/ Christopher Cox
    Name/Title:Christopher Cox, President
    Date:06/03/2025
     
    Population Health Partners GP, LLC
     
    Signature:/s/ Christopher Cox
    Name/Title:Christopher Cox, Member
    Date:06/03/2025
     
    Christopher Whitten Bernard
     
    Signature:/s/ Christopher Whitten Bernard
    Name/Title:Christopher Whitten Bernard
    Date:06/03/2025
     
    Christopher T. Cox
     
    Signature:/s/ Christopher T. Cox
    Name/Title:Christopher T. Cox
    Date:06/03/2025
     
    Clive A. Meanwell
     
    Signature:/s/ Clive A. Meanwell
    Name/Title:Clive A. Meanwell
    Date:06/03/2025
    Exhibit Information

    Exhibit 99: Joint Filing Agreement

    Get the next $MTSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    9/30/2025$54.00Overweight → Equal Weight
    Wells Fargo
    9/9/2025$77.00Outperform
    Leerink Partners
    6/20/2025$65.00Overweight
    Wells Fargo
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    See Remark 1 Fmr Llc disposed of 2,233,460 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/17/25 1:51:07 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Arch Venture Partners Xii, Llc returned 26,816,808 shares to the company (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/14/25 6:34:16 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER Lang Matthew returned 12,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/13/25 9:20:03 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:15:35 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:04:05 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:01:33 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    SEC Filings

    View All

    SEC Form 15-12G filed by Metsera Inc.

    15-12G - Metsera, Inc. (0002040807) (Filer)

    11/24/25 8:36:08 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

    SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

    11/17/25 1:59:38 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Metsera Inc.

    SCHEDULE 13D/A - Metsera, Inc. (0002040807) (Subject)

    11/14/25 6:22:29 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer Completes Acquisition of Metsera

    Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer's Internal Medicine portfolio Positions Pfizer to lead in one of the most dynamic and high-growth therapeutic areas Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. "This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resou

    11/13/25 11:26:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

    Revised transaction values Metsera at up to $86.25 per shareMetsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with PfizerTransaction creates real, certain and immediate value for Metsera's stockholders and ensures Metsera's important drug candidates can emerge as key competitors available to all patientsNEW YORK, Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value

    11/7/25 9:32:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Issues Statement in Response to Litigation Ruling

    NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer: "Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restraining order to block Metsera's Board of Directors from acting in the best interests of shareholders. Separately, Pfizer has reiterated it will continue to spuriously litigate. As we have previously noted, Pfizer's litigation arguments are nonsense. Metsera's Board of Directors will continue to stand firm on behalf of shareholders and patients." Disclosure Notice This rel

    11/5/25 7:17:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Metsera downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Metsera from Overweight to Equal Weight and set a new price target of $54.00

    9/30/25 8:33:25 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Metsera with a new price target

    Leerink Partners initiated coverage of Metsera with a rating of Outperform and set a new price target of $77.00

    9/9/25 7:59:28 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Metsera with a new price target

    Wells Fargo initiated coverage of Metsera with a rating of Overweight and set a new price target of $65.00

    6/20/25 7:54:18 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Financials

    Live finance-specific insights

    View All

    Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

    Revised transaction values Metsera at up to $86.25 per shareMetsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with PfizerTransaction creates real, certain and immediate value for Metsera's stockholders and ensures Metsera's important drug candidates can emerge as key competitors available to all patientsNEW YORK, Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value

    11/7/25 9:32:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    /C O R R E C T I O N -- Metsera, Inc./

    In the news release, Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior", issued 04-Nov-2025 by Metsera, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should begin "Shortly thereafter,..." rather than "On the same day,...", and the third paragraph, first sentence, should read "...representing up to $24.00 per share in cash (up from $21.25)..." rather than "...representing up to $24.00 per share in cash (up from $22.50)..." as originally issued inadvertently. The complete, corrected release follows: Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Ame

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

    Novo Nordisk Amended Proposal Values Metsera at up to $86.20 per Share, a Total of Approximately $10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $70.00 per Share, a Total of Approximately $8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nord

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care